MENLO TIMES

Tamarind Bio , developing state-of-the-art molecular AI models usable out of the box, with no ML or infrastructure expertise required, so scientists can focus on drug discovery and research, led by Deniz Kavi and Sherry Liu, has announced  $13.6M fundraise, including a $12M series A led by Dimension Capital , with participation from Y Combinator . As AI becomes embedded in real drug discovery workflows, no longer confined to experimental projects, life sciences organizations

Aerska , a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, led by Jack O’Meara, Stuart Milstein, Dave Hardwicke, and others, has raised  $39 million in Series A financing led by EQT Dementia Fund  and age1 , with participation from Iaso Ventures , alongside existing investors. Total funding has reached $60 million, following a seed round in October 2025. The funding will support the development of brain shuttle technology to enh

Biorce , a Barcelona-based health AI company specialized in applying artificial intelligence to the design and execution of clinical trials, led by Pedro Coelho,   Clara Bernardes, José Faria, Diogo Pisoeiro, and others, has raised $52.5 million in a Series A round. The financing includes new investment from DST Global Partners , with existing investors Norrsken VC  and YZR Capital  increasing their participation, alongside participation from Mustard Seed Maze  and Endeavor C

Mantis Biotech , the infrastructure powering human-in-computer models, led by Georgia Witchel, has announced $6.3 Million seed round, led by  Decibel Partners , with participation from  StoryHouse Ventures , Y Combinator , Pioneer Fund , Spot VC , and Fenwick . The Problem: The challenge isn’t a lack of data; it’s messy, fragmented, and hard-to-use data. Massive volumes of biological, performance, and operational information exist, but are scattered across systems and formats

ErVimmune , a biotechnology company developing next-generation therapeutic vaccines targeting new families of ‘unconventional’ tumor antigens derived from human endogenous retroviruses (HERVs), led by Stéphane Depil, Nathalie Donne, and others, has announced the first closing of its Series A financing. The company has raised €17 million ($19.8M) from an international investor syndicate. Existing shareholder Seventure Partners  (Paris, France) participated in the fundraising,

Proxima Bio , unlocking a new chapter in medicine by making protein interactions programmable, led by Zachary Carpenter, Luca Naef, and others, has secured an oversubscribed $80M seed financing led by DCVC , with participation from NVentures (NVIDIA’s venture capital arm), Braidwell , Roivant , AIX Ventures , Yosemite, Magnetic Ventures , Alexandria Venture Investments, Modi Ventures , and additional strategic and institutional investors. As part of the financing, the compan

Nuclera , the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, led by Michael Chen, Gordon Mcinroy, and others, announced  a USD $12 million financing extension, bringing the Company’s total Series C funding to USD $87 million, led by  Elevage Medical Technologies  and Jonathan Milner, joined by existing investors British Business Bank  and GK Goh . The investment will acc

Avenue Biosciences , the protein engineering platform enhancing production yield and the quality of your end product, led by Tero-Pekka Alastalo, Katja Rosti, Veli-Pekka Jaakola, Juulia Simonen, and Anton Klavus, has secured  $5.7M in seed extension funding round co-led by Balnord  and  Tesi , with support from existing investors  Voima Ventures , Inventure ,  University of Helsinki , and Dimerent, to scale a high-throughput protein engineering technology that accelerates the

Boltz , helping every scientist reshape biology, led by Gabriele Corso, Jeremy Wohlwend, and Saro Passaro, announced  its launch with $28 Million Seed Round from Zetta , Amplify , a16z , and strategic angels, including Clement Delangue (CEO of Hugging Face), Factorial Capital , and Obvious Ventures . AI-powered molecular modeling is advancing rapidly, offering the potential to make biology programmable, digitize experiments, and accelerate drug development. However, emerging

Biographica , developing cutting-edge deep learning and knowledge graph technology to identify and prioritise high-value targets for crop gene-editing, led by Cecily Price and Dominic Hall, PhD, has raised £7 million in a funding round led by  Faber VC , with participation from SuperSeed , Cardumen Capital , The Helm , EQT Foundation , and Sie Ventures . The round also included existing investors Chalfen Ventures , Entrepreneurs First , Nucleus Capital , Dhyan Ventures , Sara

AIO , an Estonian biotechnology company developing sustainable, non-animal fats and oils through innovative fermentation processes, led by Nemailla Bonturi, PhD, Petri-Jaan Lahtvee, PhD, Mary-Liis Kütt, PhD, and others, has been awarded  a €1.2 million grant from Enterprise Estonia  to advance its new project FERM-OIL. The total budget of the project is €2.3 million. Over three years, the project will scale ÄIO’s Flavoured Fat, a lipid-rich yeast ingredient with umami taste,

Chai Discovery , engineering better molecules using artificial intelligence, led by Joshua Meier  and Matthew McPartlon , has secured  $130 million Series B financing round co-led by Oak HC/FT  and General Catalyst , with participation from Thrive Capital , OpenAI , Menlo Ventures , SV Angel , and others, alongside new investors Emerson Collective  and Glade Brook , valuing the company at $1.3 Billion. The Series B round brings Chai’s total funding to more than $225 million.

EpilepsyGTx , a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, led by Nicolas Koebel, Prof. Dimitri Kullmann, Dr. Joanne Broadhead, and Dr. Luiz Almeida Silva, has secured  $33 million in a Series A financing from XGEN Venture, the British Business Bank, and a global biopharmaceutical company. Taylor Wessing LLP advised EpilepsyGTx on the round, A&O Shearman advised XGEN Venture, and Panmure Liberum Cambr

Artios Pharma Limited , a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer, led by Michael T. Andriole, Christine Silverstein, Graeme Smith, Ian Smith, and others, has announced  the successful close of an oversubscribed $115 million Series D financing, co-led by founding investor SV Health Investors  and new investor RA Capital Management , with participation from new investor Janus Henderson Invest

Self.co , a Lithuania-based company, helping you uncover the true cause of your symptoms and guide you toward the right path to better health, led by Tautvydas Gylys, Gintautas Gylys, and Juozapas Zabukas, has secured  €2.56 million in funding, including €1.2 million led by  Iron Wolf Capital , joined by  Coinvest , NGL Ventures , and several angel investors, and a €1.36 million government grant from Innovation Agency Lithuania . Nearly 40% of people worldwide suffer from all

LambdaVision , developer of protein-based artificial retinas, led by Nicole L. Wagner, Jordan A. Greco, and Robert R. Birge, has secured  $7 million seed funding round co-led by Seven Seven Six  and Aurelia Foundry Fund , with additional support from Seraphim Space , providing runway into 2027. Millions worldwide lose their vision each year to retinal diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), with limited treatment options. The new

Cellcolabs , manufacturing High-Quality Mesenchymal Stromal Cells, led by Petter Hallman, Mattias Bernow, Lina Sörvik, Heidi Stensmyren, and others, has raised  $12 million in a round led by Titian Capital. Global demand for regenerative therapies is surging, yet high costs and limited production still restrict access for many patients. Stockholm-based Cellcolabs, founded in 2021 by Dr. Mattias Bernow, aims to change this through industrial-scale stem cell manufacturing. Its

Adaptam Therapeutics , a pioneering company in cancer immunotherapies specifically targeting the immunosuppressive myeloid tumor microenvironment, led by Asis Palazon, Pablo Cironi, Salvatore Cappadona, and José M. Mato, has secured  a €3 million (~$3.5 million) pre-seed financing round led by Criteria Bio Ventures . As part of the round, Criteria Bio Ventures’ Salvatore Cappadona, PhD, and Pablo Cironi, PhD, join Adaptam’s board of directors. The €3M funding will advance Ada

Continue Research , a 2-year-old research effort to identify and study upstream mechanisms in biology, started by Deepinder Goyal, has announced a $25 million fund to back researchers, funded by personal investment, and is not a part of Eternal. The next breakthroughs in aging biology are hiding in plain sight, emerging not from added complexity but from uncovering foundational mechanisms that control everything downstream. A $25M fund supports researchers testing ideas so si

NewLimit , a biotechnology company focused on human longevity, led by Blake Byers, Brian Armstrong, Cathy O'Hare, and Jacob Kimmel, has secured  an additional $45 million from Eli Lilly and Company, Duke Management Co., Section 32, and others, bringing its market capitalization to $1.62 billion. Insiders, including Kleiner Perkins, Dimension, Abstract, Human Capital, and Boost, also participated. Significant progress has been made in developing medicines that rejuvenate aging